BACKGROUND: Serotonin 5-HT2A and metabotropic glutamate 2 (mGlu2) are neurotransmitter G protein-coupled receptors (GPCRs) involved in the signaling mechanisms underlying psychosis and schizophrenia treatment. Previous findings in mGlu2 knockout (KO) mice suggested that mGlu2 is necessary for head-twitch behavior, a rodent phenotype characteristic of hallucinogenic 5-HT2A receptor agonists. However, the role of mGlu2 in the behavioral effects induced by antipsychotic drugs remains poorly understood. Here, we tested antipsychotic-like behavioral phenotypes induced by the atypical antipsychotic clozapine in mGlu2-KO mice and wild-type control littermates. METHODS: Locomotor activity was tested in mGlu2-KO mice and control littermates injected (i.p.) with clozapine (1.5 mg/kg) or vehicle followed by MK801 (0.5 mg/kg), PCP (7.5 mg/kg), amphetamine (6 mg/kg), scopolamine (2 mg/kg), or vehicle. Using a virally (HSV) mediated transgene expression approach, the role of frontal cortex mGlu2 in the modulation of MK801-induced locomotor activity by clozapine treatment was also evaluated. RESULTS: The effect of clozapine on hyperlocomotor activity induced by the dissociative drugs MK801 and phencyclidine (PCP) was decreased in mGlu2-KO mice as compared to controls. Clozapine treatment, however, reduced hyperlocomotor activity induced by the stimulant drug amphetamine and the deliriant drug scopolamine in both wild-type and mGlu2-KO mice. Virally mediated over-expression of mGlu2 in the frontal cortex of mGlu2-KO mice rescued the ability of clozapine to reduce MK801-induced hyperlocomotion. CONCLUSION: These findings further support the existence of a functionally relevant crosstalk between 5-HT2A and mGlu2 receptors in different preclinical models of antipsychotic activity.
BACKGROUND:Serotonin5-HT2A and metabotropic glutamate 2 (mGlu2) are neurotransmitter G protein-coupled receptors (GPCRs) involved in the signaling mechanisms underlying psychosis and schizophrenia treatment. Previous findings in mGlu2 knockout (KO) mice suggested that mGlu2 is necessary for head-twitch behavior, a rodent phenotype characteristic of hallucinogenic 5-HT2A receptor agonists. However, the role of mGlu2 in the behavioral effects induced by antipsychotic drugs remains poorly understood. Here, we tested antipsychotic-like behavioral phenotypes induced by the atypical antipsychotic clozapine in mGlu2-KO mice and wild-type control littermates. METHODS: Locomotor activity was tested in mGlu2-KO mice and control littermates injected (i.p.) with clozapine (1.5 mg/kg) or vehicle followed by MK801 (0.5 mg/kg), PCP (7.5 mg/kg), amphetamine (6 mg/kg), scopolamine (2 mg/kg), or vehicle. Using a virally (HSV) mediated transgene expression approach, the role of frontal cortex mGlu2 in the modulation of MK801-induced locomotor activity by clozapine treatment was also evaluated. RESULTS: The effect of clozapine on hyperlocomotor activity induced by the dissociative drugs MK801 and phencyclidine (PCP) was decreased in mGlu2-KO mice as compared to controls. Clozapine treatment, however, reduced hyperlocomotor activity induced by the stimulant drug amphetamine and the deliriant drug scopolamine in both wild-type and mGlu2-KO mice. Virally mediated over-expression of mGlu2 in the frontal cortex of mGlu2-KO mice rescued the ability of clozapine to reduce MK801-induced hyperlocomotion. CONCLUSION: These findings further support the existence of a functionally relevant crosstalk between 5-HT2A and mGlu2 receptors in different preclinical models of antipsychotic activity.
Authors: José L Moreno; Terrell Holloway; Laura Albizu; Stuart C Sealfon; Javier González-Maeso Journal: Neurosci Lett Date: 2011-01-27 Impact factor: 3.046
Authors: M Yokoi; K Kobayashi; T Manabe; T Takahashi; I Sakaguchi; G Katsuura; R Shigemoto; H Ohishi; S Nomura; K Nakamura; K Nakao; M Katsuki; S Nakanishi Journal: Science Date: 1996-08-02 Impact factor: 47.728
Authors: W E Fantegrossi; J Simoneau; M S Cohen; S M Zimmerman; C M Henson; K C Rice; J H Woods Journal: J Pharmacol Exp Ther Date: 2010-09-21 Impact factor: 4.030
Authors: Matthew R Whorton; Michael P Bokoch; Søren G F Rasmussen; Bo Huang; Richard N Zare; Brian Kobilka; Roger K Sunahara Journal: Proc Natl Acad Sci U S A Date: 2007-04-23 Impact factor: 11.205
Authors: Matthew R Whorton; Beata Jastrzebska; Paul S-H Park; Dimitrios Fotiadis; Andreas Engel; Krzysztof Palczewski; Roger K Sunahara Journal: J Biol Chem Date: 2007-11-22 Impact factor: 5.157
Authors: Søren G F Rasmussen; Brian T DeVree; Yaozhong Zou; Andrew C Kruse; Ka Young Chung; Tong Sun Kobilka; Foon Sun Thian; Pil Seok Chae; Els Pardon; Diane Calinski; Jesper M Mathiesen; Syed T A Shah; Joseph A Lyons; Martin Caffrey; Samuel H Gellman; Jan Steyaert; Georgios Skiniotis; William I Weis; Roger K Sunahara; Brian K Kobilka Journal: Nature Date: 2011-07-19 Impact factor: 49.962
Authors: Salvador Sierra; Karan H Muchhala; Donald K Jessup; Katherine M Contreras; Urjita H Shah; David L Stevens; Jennifer Jimenez; Xiomara K Cuno Lavilla; Mario de la Fuente Revenga; Kumiko M Lippold; Shanwei Shen; Justin L Poklis; Liya Y Qiao; William L Dewey; Hamid I Akbarali; M Imad Damaj; Javier González-Maeso Journal: Neuropharmacology Date: 2022-02-17 Impact factor: 5.273
Authors: Mario de la Fuente Revenga; Bohan Zhu; Christopher A Guevara; Lynette B Naler; Justin M Saunders; Zirui Zhou; Rudy Toneatti; Salvador Sierra; Jennifer T Wolstenholme; Patrick M Beardsley; George W Huntley; Chang Lu; Javier González-Maeso Journal: Cell Rep Date: 2021-10-19 Impact factor: 9.423